Regeneron’s $500M fund spotlights corporate venture’s influential role in biotech
When Regeneron announced a $500 million corporate venture capital fund last week, it was the first time in years that a storied large pharma had done so.
The company said it’s investing $100 million a year for five years.
“Our goal is to cultivate an ecosystem where the next generation of biotech companies can thrive, drawing on the lessons learned and successes achieved at Regeneron and throughout our careers,” Michael Aberman, one of the fund’s leaders, said in the press release at the time.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
